PT - JOURNAL ARTICLE AU - Pelletier, Daniel AU - Rennert, Tony AU - Chang, Martha AU - Decunto, Santi AU - Cen, Steven TI - myMS; A Comprehensive Patient-Centered Mobile App to Monitor MS at Home (P3.2-003) DP - 2019 Apr 09 TA - Neurology PG - P3.2-003 VI - 92 IP - 15 Supplement 4099 - http://n.neurology.org/content/92/15_Supplement/P3.2-003.short 4100 - http://n.neurology.org/content/92/15_Supplement/P3.2-003.full SO - Neurology2019 Apr 09; 92 AB - Objective: The overall aim of this project is to develop and validate novel digital technologies to capture disease characteristics and to empower patients with multiple sclerosis (MS). A pilot study was conducted using myMS, a comprehensive smartphone application, to compare its active tasks against clinical metrics traditionally used in MS.Background: Digital health products offer a new data collection strategy and personalized disease management tools. They are gradually winning out on accessibility, efficiency, accuracy and cost effectiveness compared to traditional data collection methods for complex diseases like MS where patients experience daily fluctuating symptoms. Since this technology is scalable, it can allow the collection of a high-quality BigData set worldwide.Design/Methods: myMS uses a comprehensive approach to collect clinical (ambulation, cognition, vision, QOL, Rx, diet, MS and childhood history, exercise habits, comorbidities), genetic (~1,000,000 SNPs, FDA-approved 23 and Me reports), and MRI (visualization and quantification) data that could interface with wearable devices (iPhone or Android). The pilot study included 200 U.S. participants who used myMS and a sub-study (n=75) conveniently sampled at USC to compare its active tasks (6Mapp, COGapp, VISapp) against EDSS, T25FW, Symbol-Digit-Modality-Test (SDMT), and low contrast visual acuity (LCVA).Results: After uploading MRI images on a dedicated website, 200 participants completed enrollment from home and met inclusion criteria based on MRI dissemination in time. Participants were able to register and receive 23 and Me genetic kits at home and complete surveys and active tasks. Cross-sectional Spearman correlation analysis showed modest to strong correlation (p<0.01) between 6Mapp-25FWT (r=−0.85); 6Mapp-EDSS (r=−0.31); COGapp-SDMT (r=0.69); and VISapp-LCVA (r=0.67).Conclusions: myMS can be used successfully outside of clinical visits with minimal supervision and instructions. Frequent notifications, personalized dashboard, and incentives such as genetic reports and browsing of MRI images increase participation and adherence. 6Mapp, COGapp, VISapp were significantly correlated with EDSS, 25FWT, SDMT, and LCVA, providing preliminary validation of myMS.Disclosure: Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Rennert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Omphalos Medical. Dr. Rennert has received compensation for serving on the Board of Directors of Omphalos Medical. Dr. Chang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Omphalos Medical. Dr. Chang has received compensation for serving on the Board of Directors of Omphalos Medical. Dr. Decunto has nothing to disclose. Dr. Cen has nothing to disclose.